The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tumors, emphasizing the importance of molecular profiling.